Hyaluronidase

Identification

Name
Hyaluronidase
Accession Number
DB14740
Description

Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.8 The action of hyaluronidase was first described in 1936, and named in 1939.2 Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.2 Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.5

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.8

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Hialuronidasa
  • Hyaluronidase
  • Hyaluronidase (bovine)
  • Hyaluronidase bovine
  • hyaluronidase-fihj
  • hyaluronidase-zzxf
  • Hyaluronidase, bovine
  • Hyaluronidasum
  • Hyaluronoglucosaminidase

Pharmacology

Indication

Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.8 Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.8

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Hyaluronidase cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid.4,8 Hyaluronic acid is a key component of the extracellular matrix.3 Injection of hyaluronidase with other fluids, drugs, or radiopaque agents improves the ability of these other compounds to permeate the extracellular space more easily.4,8

TargetActionsOrganism
UHyaluronic acid
modulator
metabolizer
Humans and other mammals
UTransforming growth factor beta-1
inhibitor
Humans
Absorption

Data regarding the absorption of hyaluronidase are not readily available.8

Volume of distribution

Data regarding the volume of distribution of hyaluronidase are not readily available.8

Protein binding

Data regarding the protein binding of hyaluronidase are not readily available.8

Metabolism

Data regarding the metabolism of hyaluronidase is not readily available.8 However, protein drugs are expected to be degraded by proteases and other catalytic enzymes to smaller peptides and amino acids.1

Route of elimination

After nonspecific proteolysis, the amino acids from protein drugs are reused for protein synthesis or further broken down and eliminated by the kidneys.1,7

Half-life

Hyaluronidase has a half life of two minutes, but a duration of action of 24-48 hours due to its high potency.6,7

Clearance

Data regarding the clearance of hyaluronidase are not readily available.8

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Data regarding overdose of hyaluronidase is not readily available.8 In the even of an overdose, treat patients with symptomatic and supportive measures.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AripiprazoleThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole.
Aripiprazole lauroxilThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole lauroxil.
ArticaineHyaluronidase can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AzelastineThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.
BenzatropineThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine.
BenzocaineHyaluronidase can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.
BenzodiazepineThe therapeutic efficacy of Benzodiazepine can be decreased when used in combination with Hyaluronidase.
Benzyl alcoholHyaluronidase can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.
BetamethasoneThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.
Betamethasone phosphateThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone phosphate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

International/Other Brands
Amphadase
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AmphadaseInjection150 [USP'U]/1mLSubcutaneousAmphastar Pharmaceuticals, Inc.2004-10-26Not applicableUs
HydaseInjection, solution150 [USP'U]/1mLInfiltration; Interstitial; Intramuscular; Intraocular; Retrobulbar; SubcutaneousAkorn, Inc.2015-11-052015-12-01Us
Wydase Inj 150unit/mlLiquidInfiltration; SubcutaneousWyeth Ltd.1954-12-311996-09-10Canada
Wydase Injection Liq 150 Units/mlLiquidInfiltration; SubcutaneousWyeth Ayerst Canada Inc.1994-12-312002-06-10Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
B06AA03 — Hyaluronidase
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
8KOG53Z5EM
CAS number
9001-54-1

References

General References
  1. Katsila T, Siskos AP, Tamvakopoulos C: Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev. 2012 Jan-Feb;31(1):110-33. doi: 10.1002/mas.20340. Epub 2011 Jun 22. [PubMed:21698655]
  2. Duran-Reynals F: TISSUE PERMEABILITY AND THE SPREADING FACTORS IN INFECTION : A Contribution to the Host:Parasite Problem. Bacteriol Rev. 1942 Dec;6(4):197-252. [PubMed:16350083]
  3. Walker K, Basehore BM, Goyal A, Bansal P, Zito PM: Hyaluronic Acid . [PubMed:29494047]
  4. Gilson RL, Zafar Gondal A: Hyaluronidase . [PubMed:31424747]
  5. Buhren BA, Schrumpf H, Hoff NP, Bolke E, Hilton S, Gerber PA: Hyaluronidase: from clinical applications to molecular and cellular mechanisms. Eur J Med Res. 2016 Feb 13;21:5. doi: 10.1186/s40001-016-0201-5. [PubMed:26873038]
  6. King M, Convery C, Davies E: This month's guideline: The Use of Hyaluronidase in Aesthetic Practice (v2.4). J Clin Aesthet Dermatol. 2018 Jun;11(6):E61-E68. Epub 2018 Jun 1. [PubMed:29942426]
  7. Cavallini M, Gazzola R, Metalla M, Vaienti L: The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers. Aesthet Surg J. 2013 Nov 1;33(8):1167-74. doi: 10.1177/1090820X13511970. Epub 2013 Nov 6. [PubMed:24197934]
  8. FDA Approved Drug Products: Vitrase Hyaluronidase Injection [Link]
  9. FDA News Release: FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional [Link]
KEGG Drug
D04456
RxNav
578350
Wikipedia
Hyaluronidase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedOtherCardiac Output / Dehydration / Pediatrics1
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
4CompletedTreatmentDysrhythmia, Cardiac1
4Not Yet RecruitingSupportive CareInjection site bruising1
3CompletedPreventionCardiovascular Heart Disease / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Infarction / Myocardial Ischemia1
3CompletedTreatmentAdhesive Capsulitis of Shoulder1
3CompletedTreatmentDiabetic Retinopathy (DR) / Vitreous Hemorrhage1
2CompletedScreeningAllergic Skin Reaction1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentDehydration1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionSubcutaneous150 [USP'U]/1mL
Injection, solutionInfiltration; Interstitial; Intramuscular; Intraocular; Retrobulbar; Subcutaneous150 [USP'U]/1mL
LiquidInfiltration; Subcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Kind
Small molecule
Organism
Humans and other mammals
Pharmacological action
Unknown
Actions
Modulator
Metabolizer
References
  1. FDA Approved Drug Products: Amphadase (hyaluronidase) injection [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Type iii transforming growth factor beta receptor binding
Specific Function
Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negati...
Gene Name
TGFB1
Uniprot ID
P01137
Uniprot Name
Transforming growth factor beta-1
Molecular Weight
44340.685 Da
References
  1. Chang NS: Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun. 2001 May 4;283(2):278-86. [PubMed:11327694]
  2. Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E: Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res. 1995 Aug;281(2):317-24. [PubMed:7648625]
  3. Chang NS: Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1. Am J Physiol. 1997 Dec;273(6 Pt 1):C1987-94. [PubMed:9435505]
  4. Chang NS: Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int J Mol Med. 1998 Dec;2(6):653-9. [PubMed:9850732]

Drug created on February 27, 2019 16:11 / Updated on June 30, 2020 20:41

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates